Strong net profit growth: 201%Five new drugs approved for marketingShanghai, August 28, 2024 -- Luye Pharma Group today announced its 2024 half-year results and latest developments.During the reportin...
YANTAI, China, Aug. 27, 2024-- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 363 millio...
PRINCETON, N.J., July 28, 2024 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today annou...
Shanghai, July 4, 2024 – Luye Pharma Group announced that its Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) was approved for marketing by China's Na...
The world’s first long-acting microsphere formulation for treating Parkinson’s disease is another CNS product of the company approved in the fast track processJune 20, 2024 – Luye Ph...
June 11, 2024 - Luye Pharma Group today announced that its second-generation long-acting injectable (LAI) antipsychotic Meibirui (Paliperidone Palmitate Injection) has been approved for marketing by C...
June 6, 2024 – Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Ja...
Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dul...
Boan Biotech today announced that Boluojia®, a denosumab injection (120mg) developed by the company, has been approved for marketing by China’s National Medical Products Administration (NMPA) fo...
Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
TOP